Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | 0.00% | -4.20% | +43.76% |
Financials (USD)
Sales 2024 * | 85.11M | Sales 2025 * | 60.64M | Capitalization | 291M |
---|---|---|---|---|---|
Net income 2024 * | -91M | Net income 2025 * | -132M | EV / Sales 2024 * | 3.42 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.8 x |
P/E ratio 2024 * |
-3.93
x | P/E ratio 2025 * |
-3.12
x | Employees | 449 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 15.06% |
Latest transcript on Adaptimmune Therapeutics plc
1 week | -4.20% | ||
Current month | -4.20% | ||
1 month | -16.79% | ||
3 months | -8.80% | ||
6 months | +108.41% | ||
Current year | +43.76% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 57 | 07-12-31 | |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 15-02-28 |
Gavin Wood
DFI | Director of Finance/CFO | 54 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | Oct. 31 |
Andrew Allen
BRD | Director/Board Member | 57 | 23-05-31 |
David Mott
CHM | Chairman | 58 | 14-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 1.14 | 0.00% | 993,489 |
24-05-08 | 1.14 | +3.64% | 975,286 |
24-05-07 | 1.1 | -4.35% | 1,035,004 |
24-05-06 | 1.15 | -3.36% | 842,132 |
24-05-03 | 1.19 | 0.00% | 852,996 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.76% | 291M | |
+2.97% | 108B | |
+10.21% | 104B | |
+2.01% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-37.64% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |
- Stock Market
- Equities
- ADAP Stock